GIVEN BRUCE D 4

Accession 0001209191-20-026230

CIK 0000879407other

View on SEC.gov Company Profile

Filed

Apr 28, 8:00 PM ET

Accepted

Apr 29, 7:19 PM ET

Size

40.8 KB

Accession

0001209191-20-026230

Insider Transaction Report

Form 4

Period: 2020-04-27

ARROWHEAD PHARMACEUTICALS, INC.ARWR

GIVEN BRUCE D

Chief Operating Officer

Transactions

Sale
Common Stock
2020-04-27$40.00/sh−100$4,000→ 851,634 total
Sale
Common Stock
2020-04-28$40.00/sh−830$33,200→ 851,847 total
Exercise/Conversion
Stock Option (right to buy)
2020-04-28−830→ 329,560 total
Exercise: $5.19From: 2012-03-01Exp: 2022-02-16→ Common Stock (830 underlying)
Exercise/Conversion
Common Stock
2020-04-28$7.75/sh+500$3,875→ 852,134 total
Exercise/Conversion
Common Stock
2020-04-28$4.75/sh+1,200$5,700→ 854,788 total
Exercise/Conversion
Stock Option (right to buy)
2020-04-28−500→ 333,044 total
Exercise: $7.75From: 2015-04-06Exp: 2025-03-06→ Common Stock (500 underlying)
Exercise/Conversion
Stock Option (right to buy)
2020-04-28−1,200→ 330,390 total
Exercise: $4.75From: 2013-10-01Exp: 2023-09-21→ Common Stock (1,200 underlying)
Sale
Common Stock
2020-04-27$40.00/sh−200$8,000→ 851,734 total
Exercise/Conversion
Common Stock
2020-04-28$14.54/sh+1,454$21,141→ 853,588 total
Sale
Common Stock
2020-04-28$40.00/sh−213$8,520→ 851,634 total
Exercise/Conversion
Common Stock
2020-04-28$5.20/sh+213$1,108→ 855,831 total
Sale
Common Stock
2020-04-28$40.00/sh−1,200$48,000→ 852,677 total
Exercise/Conversion
Stock Option (right to buy)
2020-04-28−213→ 329,347 total
Exercise: $5.20From: 2012-04-01Exp: 2021-10-26→ Common Stock (213 underlying)
Exercise/Conversion
Common Stock
2020-04-27$5.19/sh+200$1,038→ 851,934 total
Exercise/Conversion
Common Stock
2020-04-28$5.19/sh+830$4,308→ 855,618 total
Sale
Common Stock
2020-04-28$40.00/sh−500$20,000→ 855,331 total
Sale
Common Stock
2020-04-28$40.00/sh−1,454$58,160→ 853,877 total
Sale
Common Stock
2020-04-28$40.00/sh−204$8,160→ 851,430 total
Sale
Common Stock
2020-04-28$40.00/sh−700$28,000→ 850,730 total
Exercise/Conversion
Stock Option (right to buy)
2020-04-27−200→ 333,544 total
Exercise: $5.19From: 2012-03-01Exp: 2020-02-16→ Common Stock (200 underlying)
Exercise/Conversion
Stock Option (right to buy)
2020-04-28−1,454→ 331,590 total
Exercise: $14.54From: 2014-03-01Exp: 2024-02-06→ Common Stock (1,454 underlying)

Footnotes (3)

[F1]Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
[F2]The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.01, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
[F3]Represents first vesting date. Option vested over four years from date of grant.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

ARROWHEAD PHARMACEUTICALS, INC.

CIK 0000879407

→

Entity typeother

Related Parties

filerCIK 0001219384

Filing Metadata

Form type: 4
Filed: Apr 28, 8:00 PM ET
Accepted: Apr 29, 7:19 PM ET
Size: 40.8 KB

View on SEC.gov